Naveen Basappa, MD

A touching tribute to the imitable Dr. Anil Kapoor at #CKCF24 . A remarkable mentor, urologist and one of the kindest, and most witty people in any room. He will be dearly missed and has forever left a legacy in the world of #RCC . @CanUrolAssoc

Another great #CKCis OC meeting at #CKCF24. Thank you to all of our sites for their continued hard effort and to our supporters! #kidneycancer #registry #Canadian @nbasappaCCI @RodBreau @SiTanguay @RahulBansal_13 @robert_bick @UroOncMD @DrJeffreyGraham

Poster #366: Real-world practice patterns, treatment-related toxicity, and survival outcomes in older pts with mRCC. #CKCis #GU24 #RWE #registry #kidneycancer @MSoleimani_MD @SiTanguay @lalaniMD @DrDanielHeng @nbasappaCCI @RodBreau @DrJeffreyGraham

Poster #367: Real-world efficacy and toxicity of Ipi and Nivo for first line treatment of mRCC. #ckcis #kidneycancer #GU24 @christinacanil @nbasappaCCI @RodBreau @SiTanguay @DSoulieresMD @lalaniMD @DrJeffreyGraham @UroOncMD @BBhindi

Poster #393: Ipi/Nivo compared to Axi/Pembro in mRCC. #CKCis #RWE #registry #GU24 #CanadianData @hyejeeohm @nbasappaCCI @RodBreau @DrJeffreyGraham @DrDanielHeng @UroOncMD @SiTanguay @lalaniMD @BBhindi

Poster #416: Impact and Timing of Immunotherapy and CN on Outcomes in mRCC. #CKCis #GU24 #RWE #Canadian #kidneycancer @LarryParkMD @nbasappaCCI @RodBreau @DrDanielHeng @Ramysaleh86 @SiTanguay @DrJeffreyGraham @lalaniMD @UroOncMD @Dominick_Bosse

Poster #389: Management, Outcomes, and Predictors of Recurrence and Survival in Localized Chromophobe RCC. #CKCis #GU24 #RWE #kidneycancer #chromophobeRCC #chromophobe @nbasappaCCI @RodBreau @RicardoARendon @SiTanguay @UroOncMD @RahulBansal_13 @BBhindi

New table highlighting results in IMDC favorable risk RCC across IO-based doublets and nivo/pembro monotx trials. Major caveats about small subsets and differing follow-up, but interesting observations emerge. Thanks to @DrChoueiri and Mike Atkins for help assembling data.

Tragic case of fatal #5FU toxicity - grateful that Dr. Anil Kapoor’s family has taken this issue public. @CBCTheNational Hopefully will push resources for routine DPYD screening 🇨🇦 ➡️@BCCancer adopted DPYD testing in BC last year🙏 ➡️ we need to learn more about variants in racialized pop’n cbc.ca/player/play/22…

@hjwang26 @AdamKinnaird Great stuff! Congratulations @hjwang26 and @AdamKinnaird ! Looking forward to more great work!

Grateful for Dr Akinnaird and his guidance, our paper on the microUS guided prostate biopsy made the cover of CUAJ! 🥳@AdamKinnaird

Accelerated approval for EV+pembrolizumab- ORR Cohorts A &K of 68%! Potentially transformative for advanced urothelial ca- all eyes now on EV-302. Kudos to an amazing study team! @MSKCancerCenter @MattMilowsky @DrChrisHoimes @DanielPetrylak @TomFlaigMD bit.ly/3zvmvnI

The publication of the IMDC prognostic groups in 2009 raises the question of whether they are still relevant in the era of "contemporary" treatments. Answer: YES! Valid thru! @EUplatinum @OncoAlert @DrDanielHeng @DrChoueiri @DrRanaMcKay @lalaniMD @ASCO doi.org/10.1016/j.euru…

McDavid: 498 career assists Matthews: 497 career points That’s all what needs to be said

1 Meeting #CKCF2022 4 teams...some injuries later! We have a winning team w/ @lukelavallee @_kmcalpine @RodBreau . Thank you participants! Are we having bingo next year @anilkapoormd ? @lalaniMD @ShaanDudani @BBhindi @Dominick_Bosse @TiffanyPizioli @SiTanguay @nbasappaCCI

#CKCF22: Gloves are off for fun and informative debate on adjuvant IO in #RCC - captures contemporary talking points in this evolving space! Yay @DrRanaMcKay Nay @anilkapoormd @CanUrolAssoc @SiTanguay @DrJeffreyGraham @Merregan @lukelavallee

#CKCF22 @Merregan (@DanaFarber) asks how we could reassess #RCC prognostic factors in current IO era… - time-varying approach, - possibility of additional factors, - goals for future models: is “simple” always best? @CanUrolAssoc @DrJeffreyGraham @SiTanguay

Excited to kick-off #CKCF22 in-person, Oct 13-15! Thrilled to have 🇨🇦 #RCC collaborators elbow-to-elbow, and of course welcome our international speakers — @DrRanaMcKay (@UCSDHealth) & @Merregan (@DanaFarber) @CanUrolAssoc @ckcis_ca @HotelXToronto @lukelavallee

Day 2 of #CKFC22, AM sessions focusing on: - approaches to localized #RCC, renal masses - predicting recurrence post surgery @RodBreau - tumour board - prognostic factors in IO era @Merregan - the great debate! adjuvant IO @DrRanaMcKay vs @anilkapoormd

On behalf of the meeting chair @anilkapoormd and scientific program co-chairs @lalaniMD and Luke Lavallee welcome to #ckcf22.